Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.38 |
| ▸ | LPL | P06858 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381769 | 0.85 | RARA (0.39) | LPLLIPGTTRCA1CA2 | |
| SCHEMBL12017815 | 0.76 | CRHR1 (0.44) | CRHR1ARS1PR1KDM4EALDH1A1 | |
| SCHEMBL382234 | 0.76 | LPL (0.39) | LPLLIPGTTRCA1CA2 | |
| SCHEMBL381497 | 0.75 | LPL (0.42) | LPLLIPGKDM4ETTRCA1 | |
| SCHEMBL1927873 | 0.75 | GAA (0.50) | CRHR1ARKDM4EMEN1NPC1 | |
| SCHEMBL382442 | 0.75 | HRH4 (0.43) | CRHR1ARKDM4EMEN1ALDH1A1 | |
| Water SCHEMBL27705830 | 0.73 | CRHR1 (0.39) | CRHR1ARS1PR1KDM4EMEN1 | |
| Water SCHEMBL27705828 | 0.73 | CRHR1 (0.39) | CRHR1ARS1PR1KDM4EMEN1 | |
| SCHEMBL16247253 | 0.73 | CRHR1 (0.42) | CRHR1ARALDH1A1 | |
| SCHEMBL3529075 | 0.73 | HCAR3 (0.55) | MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470871-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-25 | — | — | US | disclosed |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-11 | — | — | US | disclosed |
| US-8227507-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-24 | — | — | US | disclosed |
| EP-1831149-B1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-01-25 | — | — | EP | disclosed |
| CN-101087752-B | Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics | GALDERMA RES & DEV | 2011-11-16 | — | — | CN | disclosed |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-18 | — | — | US | disclosed |
| US-7807708-B2 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | US | disclosed |
| CN-101087752-A | Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics | GALDERMA RES & DEV (FR) | 2007-12-12 | — | — | CN | disclosed |
| EP-1831149-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066978-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS, AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | RARB, RARA, RARG | MGLL 1267/4885CRHR1 1515/4885LPL 499/4885 |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | MGLL 1877/4885CRHR1 1535/4885LPL 1157/4885 |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | MGLL 1877/4885CRHR1 1535/4885LPL 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.